On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Execs Sign Three-Year Contract Extensions, Ensuring Management Continuity

  • LXRP CEO Chris Bunka and President John Docherty have agreed to new, three-year contracts
  • The new contract agreements are designed to provide management security with continuity of key officers
  • The company recently canceled 1,140,000 stock options after negotiations with optionees

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has successfully negotiated new three-year compensation contracts with key officers Chris Bunka, CEO, and John Docherty, president. The agreements offer LXRP and its shareholders the security of pursuing corporate growth within a seamless transition by providing management continuity. The renewal agreements are retroactive to January 1, 2019 (http://nnw.fm/J20Ew).

The agreements offer both officers compensation and bonuses based on meeting certain performance criteria established by the LXRP board. The agreements also offer a one-time bonus based on consideration for the sale of any subsidiary or change of control, excluding certain circumstances, as well as continuing participation in the LXRP stock option plan.

LXRP also announced that, effective April 5, 2019, the company was canceling 1,140,000 stock options with exercise prices ranging from $0.10 to $2.06 after reaching agreements with certain optionees.

Based in British Columbia, Canada, LXRP is a biotechnology company and drug-delivery platform innovator, with DehydraTECH as its proprietary absorption technology platform. The company has developed and out-licenses its disruptive technology, which promotes healthier ingestion methods and lower overall dosing. LXRP holds a patent for oral delivery of all cannabinoids and has a growing IP portfolio that includes 10 patents granted in the United States and Australia and more than 50 patent applications worldwide across 10 patent families.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://nnw.fm/LXRP

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.networknewswire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Archives

Select A Month

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217